Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) reported EBITDA Margin of 1021.71% for Q1 2025, up 136402.0% year-over-year from N/an in Q1 2024, and up 504.25% quarter-over-quarter from 252.74% in Q4 2024.
Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 7 years of EBITDA Margin data on file, last reported at 1021.71% in Q1 2025.
- EBITDA Margin for Q1 2025 came in at 1021.71%, up 136402.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 286.8% (down 4163.0% YoY), and the FY2025 annual result was 286.8%, down 4163.0% from the prior year.
- EBITDA Margin grew to 1021.71% in Q1 2025 per WHWK's latest filing, from 252.74% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1021.71% in Q1 2025 and troughed at 3405.83% in Q1 2021.
- A 5-year average of 421.8% and a median of 266.48% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin plunged 17436 bps in 2021, then jumped 280518 bps in 2022.
- A 5-year view of EBITDA Margin shows it stood at 118.84% in 2021, then plunged by 124 bps to 266.48% in 2022, then increased by 4 bps to 256.5% in 2023, then rose by 1 bps to 252.74% in 2024, then soared by 504 bps to 1021.71% in 2025.
- Business Quant data shows WHWK's EBITDA Margin at 1021.71% in Q1 2025, 252.74% in Q4 2024, and 173.04% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1,021.71% |
| Dec 31, 2024 | -252.74% |
| Sep 30, 2024 | -173.04% |
| Jun 30, 2024 | -236.32% |
| Mar 31, 2024 | -342.31% |
| Dec 31, 2023 | -256.50% |
| Sep 30, 2023 | -273.10% |
| Jun 30, 2023 | -289.95% |
| Mar 31, 2023 | -258.05% |
| Dec 31, 2022 | -266.48% |
| Sep 30, 2022 | -343.30% |
| Jun 30, 2022 | -531.54% |
| Mar 31, 2022 | -600.65% |
| Dec 31, 2021 | -118.84% |
| Mar 31, 2021 | -3,405.83% |
| Dec 31, 2020 | 55.52% |
| Sep 30, 2020 | -1,358.87% |
| Jun 30, 2020 | 61.71% |
| Dec 31, 2018 | -413,534.42% |
| Sep 30, 2018 | 59.49% |